CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Pembrolizumab (Keytruda) classical Hodgkin Lymphoma – Details

Project Number PC0109-000
Brand Name Keytruda
Generic Name Pembrolizumab
Strength 50 mg/vial
Tumour Type Lymphoma
Indication classical Hodgkin Lymphoma (cHL)
Funding Request As monotherapy is indicated for the treatment of adult patients with refractory or relapsed classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV
Review Status Complete
Pre Noc Submission Yes
NOC Date
NOC/c Date September 8, 2017
Manufacturer Merck Canada Inc.
Sponsor Merck Canada Inc.
Submission Date July 7, 2017
Submission Deemed Complete July 14, 2017
Submission Type Initial
Prioritization Requested Requested and Granted
Stakeholder Input Deadline ‡ July 21, 2017
Check-point meeting September 6, 2017
pERC Meeting October 19, 2017
Initial Recommendation Issued November 2, 2017
Feedback Deadline ‡ November 16, 2017
pERC Reconsideration Meeting December 14, 2017
Final Recommendation Issued January 5, 2018
Notification to Implement Issued January 22, 2018
Therapeutic Area classical Hodgkin Lymphoma (cHL)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.